This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RENB Lunai Bioworks (RENB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Lunai Bioworks Stock (NASDAQ:RENB) Get Lunai Bioworks alerts:Sign Up Key Stats Today's Range$1.13▼$1.4350-Day Range$1.30▼$2.3852-Week Range$0.12▼$1.43Volume880,400 shsAverage Volume2.93 million shsMarket Capitalization$250.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. Read More Receive RENB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lunai Bioworks and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RENB Stock News HeadlinesLunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours SessionJune 16, 2026 | benzinga.comLunai Bioworks Furloughs Staff Amid Liquidity ConstraintsMarch 5, 2026 | tipranks.comArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.25 g/t. After roughly 21,000 metres of drilling, the company is closing in on its first-ever mineral resource estimate, expected in Q3 or Q4 2026. That estimate could offer the market its first real look at the scale of this emerging gold system.September 22 at 1:00 AM | Wall Street Logic (Ad)Lunai Bioworks Faces Nasdaq Delisting, Hearing ScheduledFebruary 23, 2026 | tipranks.comLunai Bioworks Secures $3.1M in Private PlacementNovember 25, 2025 | tipranks.comLunai Bioworks announces early results from AI-based platformOctober 31, 2025 | msn.comLunai Bioworks unveils new corporate identitySeptember 30, 2025 | msn.comLunai Bioworks advances biomarker discovery preclinical program in Parkinson’sSeptember 25, 2025 | msn.comSee More Headlines RENB Stock Analysis - Frequently Asked Questions How were Lunai Bioworks' earnings last quarter? Lunai Bioworks Inc. (NASDAQ:RENB) posted its quarterly earnings data on Wednesday, February, 19th. The company reported ($0.20) earnings per share for the quarter. When did Lunai Bioworks' stock split? Lunai Bioworks shares reverse split on Monday, September 29th 2025.The 1-10 reverse split was announced on Wednesday, September 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lunai Bioworks IPO? Lunai Bioworks (RENB) raised $12 million in an IPO on the week of December 10th 2018. The company issued 2,400,000 shares at $5.00 per share. What other stocks do shareholders of Lunai Bioworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lunai Bioworks investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings2/19/2025Today9/22/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RENB CIK1527728 Webwww.enochianbio.com Phone305-918-1980FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-60.38% Return on Assets-47.04% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book1.73Miscellaneous Outstanding Shares162,390,000Free Float171,258,000Market Cap$250.24 million OptionableOptionable Beta0.54 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RENB) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersThe drone firm the Pentagon chose for next-gen defenseOne Nasdaq-listed drone company already supplies the US Army, Air Force, and Navy with mission-ready drone sys...Tomorrow Investor | SponsoredPass by August 7… or wait until 2027?Last month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredChina's dominance in rare earth processing sparks new defense rulesOn January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adve...The Tomorrow Investor | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredThe Shiller CAPE ratio now sits above 41. Before the 1929 crash, it was 32.6.The Shiller CAPE ratio now sits above 41 a level seen only once before, near the peak of the dot-com bubble. B...USA Capital Gold | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lunai Bioworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lunai Bioworks With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
